Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

被引：20

作者：

Petrich, Adam ^{[1
]}

Kahl, Brad ^{[1
]}

Bailey, Howard ^{[1
]}

Kim, Kyungmann ^{[2
]}

Turman, Nancy ^{[1
]}

Juckett, Mark ^{[1
]}

机构：

[1] Univ Wisconsin, Ctr Comprehens Canc, Dept Med, Madison, WI USA

[2] Univ Wisconsin, Ctr Comprehens Canc, Dept Biostat & Med Informat, Madison, WI USA

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 01期

关键词：

doxercalciferol; myelodysplastic syndrome; phase II study;

D O I：

10.1080/10428190701713648

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5g orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.

引用

页码：57 / 61

页数：5

共 15 条

[1]

Bikle DD, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P22

[2]

Cheson BD, 2000, BLOOD, V96, P3671

[3]

GALLAGHER JC, 1994, J BONE MINER RES, V9, P607

[4] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[5] Myelodysplasia [J].

Heaney, ML ;

Golde, DV .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) :1649-1660

[6] Vitamin D2 analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome [J].

Koeffler, HP ;

Aslanian, N ;

O'Kelly, J .

LEUKEMIA RESEARCH, 2005, 29 (11) :1259-1262

[7] 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia [J].

Kumagai, T ;

Shih, LY ;

Hughes, SV ;

Desmond, JC ;

O'Kelly, J ;

Hewison, M ;

Koeffler, HP .

CANCER RESEARCH, 2005, 65 (06) :2488-2497

[8]

Liu G, 2003, CLIN CANCER RES, V9, P4077

[9] Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1 alpha-hydroxyvitamin D-5 [J].

Mehta, RG ;

Moriarty, RM ;

Mehta, RR ;

Penmasta, R ;

Lazzaro, G ;

Constantinou, A ;

Guo, L .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :212-218

[10]

Mellibovsky L, 1998, BRIT J HAEMATOL, V100, P516

← 1 2 →